The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
about
Novel investigational drugs active as single agents in multiple myeloma.From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.PIM2 interacts with tristetraprolin and promotes breast cancer tumorigenesis.Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
P2860
The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The Novel Pan-PIM Kinase Inhib ...... ith Current Standards of Care.
@en
type
label
The Novel Pan-PIM Kinase Inhib ...... ith Current Standards of Care.
@en
prefLabel
The Novel Pan-PIM Kinase Inhib ...... ith Current Standards of Care.
@en
P2093
P50
P1476
The Novel Pan-PIM Kinase Inhib ...... ith Current Standards of Care.
@en
P2093
Ana-Alicia López-Iglesias
Antonio Garcia-Gomez
David Corbacho
Esperanza M Algarín
Laura San-Segundo
Lorena González-Méndez
María-Victoria Maetos
Montserrat Martín-Sánchez
Susana Hernández-García
Teresa Paíno
P304
P356
10.1158/1078-0432.CCR-16-0230
P407
P577
2016-07-20T00:00:00Z